Breadcrumb

Home
Topics
Hepatitis C

Hepatitis C

Publications
News
Events
Document library
Media library
Activities
Data
External links

Overview

Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs in Europe, although HCV infection is both preventable and curable. Effective interventions that target the prevention of HCV transmission and the treatment of hepatitis C are needed, particularly for so-called ‘hard to reach’ and vulnerable populations.

Featured

Increasing access to hepatitis C care through drugs services

People who inject drugs are a key population for the elimination of hepatitis C in Europe; increasing access to HCV testing and care for this group is a goal in European and national hepatitis C policies. This EMCDDA Harm Reduction initiative provides a set of new materials and tools to help countries to analyse barriers to testing at drug services, to identify solutions in collaboration with all stakeholders involved and to implement new models of care in this field.

Learn more

Publications

Publications by the EMCDDA on this topic

Filter

Keywords

Evidence for the effectiveness of interventions to prevent infections among people who inject drugs: Review of mathematical modelling studies of opioid agonist treatment and needle and syringe programmes for preventing hepatitis C transmission

2023
Evidence for the effectiveness of interventions to prevent infections among people who inject drugs: Drug treatment, needle and syringe programmes and drug consumption rooms for preventing hepatitis C, HIV and injecting risk behaviour

2023
Viral hepatitis elimination barometer among people who inject drugs in Europe

2023
Injecting drug use in Europe – the current situation (European Drug Report 2023)

2023
Drug-related infectious diseases – the current situation in Europe (European Drug Report 2023)

2023
European Drug Report 2022: Trends and Developments

2022
Drug-related infectious diseases (DRID): update from the expert network, October 2021

2022
Manual: increasing access to hepatitis C testing and care for people who inject drugs

2021
EMCDDA guide to holding a stakeholder round-table on supporting hepatitis C testing and care in drug services

2021
Increase access to HCV testing and care in drugs services — a toolkit

2021
Prison and drugs in Europe: current and future challenges

2021
European Drug Report 2021: Trends and Developments

2021
Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons

2021
Meeting report – Expert meeting on drug-related infectious diseases (DRID) 2020

2020
European Drug Report 2020: Trends and Developments

2020

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

News

Read our most recent news on this topic

Key interventions to prevent and control infections among people who inject drugs (November 2023 )
#WorldHepatitisDay: Helping to beat viral hepatitis (July 2023 )
#WorldHepatitisDay — EMCDDA practical resources to help European countries beat viral hepatitis (July 2022 )
EMCDDA launches new resources to help European countries beat viral hepatitis (July 2021 )
New EMCDDA report underlines need to scale up drug services in prisons (June 2021 )
European drug market proves resilient to COVID-19 disruption (June 2021 )
World Hepatitis Day: EMCDDA showcases hepatitis questionnaire for drug service staff to refresh knowledge and identify training needs (July 2020 )
Testing for drug-related infectious diseases — a crucial step towards meeting international health goals (May 2020 )
Hepatitis elimination barometer — focus of new report (September 2019 )
#WorldHepatitisDay: Supporting the HCV elimination agenda –– an EMCDDA initiative to increase access to hepatitis C care in drug services (July 2019 )
Latest update on drug-related infectious diseases in Europe (June 2019 )
EMCDDA at 7th International Symposium on Hepatitis Care in Substance Users (September 2018 )
World Hepatitis Day 2018 (July 2018 )
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA guidance (July 2018 )
#WorldHepatitisDay: EMCDDA joins forces with partners to address viral hepatitis elimination targets (July 2017 )

Pagination

Current page 1
Page 2
Next page
Last page

Events

Related events, meetings, conferences and more from our events calendar

World Hepatitis Summit 2024 (09 Apr 2024 to 11 Apr 2024, Lisboa, Portugal)
Joint press conference ECDC-EMCDDA (07 Nov 2023, Online)
World Hepatitis Day 2023 (28 Jul 2023)
Heroin treatment: an alternative. Background, current situation and challenges of future (16 Dec 2022, Barcelona, Spain)
The 10th International Conference on Health and Hepatitis Care in Substance Users (INHSU 2022) (19 Oct 2022 to 21 Oct 2022, Hybrid (Glasgow and online))
World Hepatitis Day 2022 (28 Jul 2022)
Spring European Testing Week 2022 (16 May 2022 to 23 May 2022)
Setting the course for Hepatitis elimination – what the EU can do to help reach the WHO 2030 goal (07 Dec 2021, Online)
European and International Testing Week launch event (22 Nov 2021 to 28 Nov 2021)
Biarritz International Congress: Addictions Toxicomanies Hépatites SIDA (ATHS) (19 Oct 2021, Online)
INHSU 2021 Virtual conference (13 Oct 2021 to 15 Oct 2021, Online)
World Hepatitis Day 2021 (28 Jul 2021)
3rd EU HCV Elimination Policy Summit (24 Mar 2021, Online)
Autumn European Testing Week (20 Nov 2020 to 27 Nov 2020)
European Drugs Summer School (EDSS) 2020 (29 Jun 2020 to 10 Jul 2020, Lisbon, Portugal)

Pagination

Current page 1
Page 2
Next page
Last page

Data

No results found for your current search criteria. Consider broadening your search.

Source data for the Viral hepatitis elimination barometer among people who inject drugs in Europe
Source data for Drug-related infectious diseases – the current situation in Europe (European Drug Report 2023)
Statistical Bulletin 2022 — drug-related infectious diseases
Statistical Bulletin 2020 — drug-related infectious diseases
Statistical Bulletin 2021 — drug-related infectious diseases
Statistical Bulletin 2019 — drug-related infectious diseases
Statistical Bulletin 2018 — drug-related infectious diseases
Statistical archive

Activities and tools

EMCDDA activities, services and tools on this topic

Increasing access to hepatitis C care through drugs services

Document library

Documents on this topic in our Document Library

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis (2023 )
Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review (2023 )
Interventions to prevent HIV and Hepatitis C among people who inject drugs: latest evidence of effectiveness from a systematic review (2011 to 2020) (2022 )
Associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe (2021 )
Luxembourg national drug report 2020 (2021 )
The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases (2020 )
Knowledge questionnaire on viral hepatitis for drug service staff (2020 )
COVID-19: information for people living with viral hepatitis (WHA) (2020 )
COVID-19: HIV prevention, treatment, care and support for people who use drugs and people in prisons (UNODC) (2020 )
HCV promotional material example: Hepatitis C: The facts (2019 )
Hepatitis C: new models of care for drugs services (2019 )
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA (2018 )
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA (2018 )
HCV policies landscape in Europe, 2018 – EMCDDA commissioned study (contract CT.16.IBS.0156.1.0) (2018 )
EASL Recommendations on Treatment of Hepatitis C 2018 (2018 )